{"id":"W2599322403","doi":"10.1200/jco.2017.35.4_suppl.tps504","title":"KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Hepatocellular carcinoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Oncology; Progressive disease; Liver disease; Cancer; Surgery; Gastroenterology; Disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001875034,0.001705546,0.001711452,0.0004504942,0.0004255303,0.00106533,0.000998033,0.001416552,0.00908766],"category_scores_gemma":[0.0009784754,0.0007551245,0.001119487,0.0004015871,0.000699039,0.000968349,0.0005058265,0.003051327,0.002590515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001175416,"about_ca_system_score_gemma":0.002003272,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001020772,"about_ca_topic_score_gemma":0.002717986,"domain_scores_codex":[0.9996021,0.0001794011,0.00002106994,0.00006048316,0.00004356746,0.0000933026],"domain_scores_gemma":[0.999337,0.00006906503,0.0001259607,0.0000449123,0.00003785358,0.000385194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.713963,0.09101847,0.008073196,0.001901128,0.00187366,0.0004769634,0.0002700966,0.002353311,0.04103079,0.0004818179,0.01419889,0.1243586],"study_design_scores_gemma":[0.7717266,0.2101993,0.009577035,0.00004501741,0.0004158121,0.0003093516,0.00003977394,0.0008374248,0.001905854,0.0001594173,0.004761291,0.00002301524],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9729763,0.004500318,0.0009821623,0.001383099,0.0003247088,0.00973546,0.004283045,0.0002989293,0.005515872],"genre_scores_gemma":[0.9699443,0.003078238,0.002178298,0.002409848,0.0002873416,0.009540937,0.005491653,0.00005096104,0.007018427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00908766,"threshold_uncertainty_score":0.03040123,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1418710922414108,"score_gpt":0.4151685850376937,"score_spread":0.2732974927962828,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}